A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.
We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive GCSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.
von Lilienfeld-Toal
Marie
M
Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund-Freud Str. 25, 53105 Bonn. m.lilienfeld.toal@uni-bonn.de
Hahn-Ast
Corinna
C
Kirchner
Hartmut
H
Flieger
Dimitri
D
Dölken
Gottfried
G
Glasmacher
Axel
A
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013997:Time Factors
D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim; D015255:Idarubicin